All News

The addition of custirsen did not improve survival for a subset of patients with prostate cancer in a phase 3 trial.

Fortunately, cancer awareness has increased, and so have treatment options. One of my goals is to encourage patients and families to maximize their use of available resources to minimize post-treatment challenges and discomfort.

Making our own decisions is empowering after facing the trauma of breast cancer.

The best use of liquid biopsies in late-stage non–small cell lung cancer (NSCLC) will be to augment tissue biopsies at initial diagnosis and to evaluate patients for second- and third-line therapies.

With more treatment options than ever, Maura N. Dickler discusses some of the deciding factors for patients with ER positive metastatic breast cancer.

Two-time cancer survivor shares her thoughts about that small, quiet voice.

Charlie Gourley discusses where Lynparza fits in with ovarian cancer care.

Alexander I. Sankin comments on some of the ongoing developments in bladder cancer.

A cancer diagnosis can send people reeling. Who should you listen to as you decide the next step? Who should you ignore?

Whoever said there's no way to make time stand still clearly never had to endure the excruciating wait for scan results.

Recent years brought many advances in the field of immunotherapy in melanoma, but more still needs to be done.

Keytruda is showing benefit to some patients with sarcoma, according to interim results from a phase 2 trial.

Surprisingly, Opdivo did not improve progression-free survival for a subset of patients with lung cancer in the CheckMate-026 trial. CURE sat down with Paul A. Bunn Jr to discuss why.

Of the possible 1,000,000 Lynch syndrome carriers in the USA alone, it is estimated that only about 5 percent have been tested.

Why know the odds if they're useless?

New standards were just established for patients undergoing surgery for DCIS.

Jorge Garcia offers insight about the benefits of Cabometyx and the drug's impact on RCC.

A recent study found that certain genetic mutations could play a role in cisplatin-induced hearing loss.

One survivor's personal experiment in finding relief from lymphedema.

Our cancer clock never stops ticking, but we can stop looking.

Randy F. Sweis talks to CURE about the future of treatment for GU cancers.

Here are 12 things I learned after hearing the words, "You have cancer."

Selumetinib plus docetaxel did not slow progression in lung cancer any more than docetaxel alone.

When used in combination, Cotellic and Zelboraf showed a significant reduction in death rates for some patients with melanoma.

Volker Heinemann says early tumor shrinkage may be a better predictor than progression-free survival in colorectal cancer.

Jonathan Riess emphasizes the importance of testing for ROS1 and TRK in patients with lung cancer so that treatment options can be explored accordingly.

Post traumatic stress disorder can occur in women who've experienced the trauma of breast cancer.